Kanabo Group PLC
3WD
Company Profile
Business description
Kanabo Group PLC is a research and development company engaged in selling a range of THC-Free retail CBD products in the markets and it is in the process of developing medical cannabis products. Its reportable segments include Primary Care and Secondary Care. The Primary Care segment, which derives key revenue, includes Tele pharma services provided by GPS and The Secondary Care segment includes the development and distribution of cannabis-derived medical and wellness products. Geographically company has a presence in the United Kingdom and Israel.
Contact
137-139 Brent Street
Churchill House
LondonNW4 4DJ
GBRT: +44 2074690930
Sector
Healthcare
Stock type
Defensive
Industry
Medical Care Facilities
Fiscal Year End
31 December 2026
Employees
16
Stocks News & Analysis
stocks
There are 3 good reasons to buy this US dividend stock today
It’s a dividend aristocrat with a healthy yield that looks significantly undervalued even after its recent rally.
stocks
Strategic reset for ASX listed share
The global search for a new CEO is over, ending investor concern about leadership uncertainty.
stocks
ASX listed bank overvalued after shares surge
Investors were pleased with results but our fair value estimate is unchanged.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,159.70 | 9.90 | -0.11% |
| CAC 40 | 8,311.74 | 28.82 | -0.35% |
| DAX 40 | 24,914.88 | 62.19 | 0.25% |
| Dow JONES (US) | 49,500.93 | 48.95 | 0.10% |
| FTSE 100 | 10,446.35 | 43.91 | 0.42% |
| HKSE | 26,567.12 | 616.03 | -2.27% |
| NASDAQ | 22,546.67 | 50.48 | -0.22% |
| Nikkei 225 | 56,941.97 | 708.57 | -1.23% |
| NZX 50 Index | 13,201.38 | 3.20 | 0.02% |
| S&P 500 | 6,836.17 | 3.41 | 0.05% |
| S&P/ASX 200 | 8,936.60 | 8.80 | -0.10% |
| SSE Composite Index | 4,082.07 | 51.95 | -1.26% |